Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Print: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v17.i2.40
pages 175-198

Inhibitors of Cell Cycle Kinases: Recent Advances and Future Prospects as Cancer Therapeutics

Andrew Stone
Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia
Robert L. Sutherland
Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia; St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, NSW, 2010, Australia
Elizabeth A . Musgrove
Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia; St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, NSW, 2010, Australia

ABSTRACT

The cell cycle is a tightly regulated series of events that governs cell replication and division. Deregulation of cell cycle kinases, e.g., cyclin-dependent kinases (CDKs), can initiate a hyper-proliferative cell phenotype and cause genomic instability, thus facilitating malignant transformation. Pharmacological agents targeting CDKs have been developed as potential anti-cancer agents for over 20 years, evolving from early pan-CDK inhibitors to second-generation inhibitors with much greater specificity and selectivity. Despite these advances in drug design and highly successful preclinical investigations, CDK inhibitors have yet to achieve their expected efficacy in clinical trials. In addition, inhibitors of other cell cycle kinases are currently progressing through clinical trials. Recent biochemical and genetic studies might be used to improve the effectiveness of cell cycle kinase inhibitors as anti-cancer agents through better drug design, therapeutic combinations, and patient selection.


Articles with similar content:

Diverse Signaling Pathways and Current Status of Molecular Targeted Treatments for Hepatocellular Carcinoma
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 4
Ali Sharif, Wafa Majeed, Bushra Akhtar, Muhammad Furqan Akhtar, Faqir Muhammad
Colorectal Cancer Management by Herbal Drug-Based Nanocarriers: An Overview
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.37, 2020, issue 1
Sujata P. Sawarkar, Krishna Baxi, Vritika Kulwal, Lokesh Kumar Bhatt
Small RNAs: The Qualified Candidates for Gene Manipulation in Diverse Clinical Pathologies
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 4
Gaurav Sharma, Kanwaljit Chopra, Indu Pal Kaur, Parveen Rishi, Sanjeev Puri
Newer Trends in Pancreatic Cancer Treatment: Genetic Alterations and the Role of Immune Therapeutic and Targeted Therapies
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 2
Abdul Kareem Khan, Mamoon Ur Rashid, Ishtiaq Hussain, Sarfraz Ahmad, Hasan Badar, Muhammad Muzammil, Sundas Jehanzeb, Deepika Sarvepalli, Muhammad Talha Khan, Asad ur Rahman, Waqas Ullah
Delivery of Biotherapeutics by Inhalation Aerosol
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.12, 1995, issue 2-3
Ralph W. Niven